雙極性情感障礙治療市場：按藥物類別、分銷管道和地區分類

Bipolar Disorder treatment Market, By Drug Class, By Distribution Channel, And by Region

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，雙極性情感障礙治療市場規模將達到 102.449 億美元，到 2033 年將達到 150.22 億美元。預計 2026 年至 2033 年的複合年成長率為 5.6%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	102.449億美元
歷史數據時期：	2020-2024	預測期：	2026-2033
2026年至2033年預測期間的複合年成長率：	5.60%	2033年市場規模預測：	150.22億美元

雙相情感障礙是一種終身疾病，但可以透過適當的藥物來控制。用於控制雙極性情感障礙症狀的藥物包括情緒穩定劑和非典型抗精神病藥物。情緒穩定劑，例如鋰，透過抑制躁狂和憂鬱症發作等情緒波動來治療躁鬱症。Cariprazine是一種非典型抗精神病藥物，適用於治療成人雙極I型障礙憂鬱症的憂鬱發作。抗憂鬱症憂鬱症合併使用，用於治療憂鬱發作。抗憂鬱症和情緒穩定劑的合併使用旨在預防雙相情感障礙患者出現躁症發作。患者的情緒和日常活動能力會經歷快速變化。雙極性情感障礙分為四種：雙極I型、雙相II型、環性心境障礙以及其他特異性和非特異性雙相及相關障礙。雙極性情感障礙患者會經歷異常強烈的情緒波動、不規律的睡眠模式和活動水平，以及情緒發作。雙極性情感障礙的診斷主要依據患者的症狀、家族病史和生活史。醫療專業人員通常會進行精神健康評估以確診雙相情感障礙。

市場動態

預計在預測期內，市場主要企業擴大採用非內部成長策略，例如併購、合約和合作，將推動市場成長。例如，2019年7月，吉瑞製藥（Gedeon Richter plc）與Hikma Pharmaceuticals Plc.達成獨家授權合約，在中東和北非（MENA）地區的特定市場銷售新型抗精神病藥物Cariprazine。此外，在此之前，2016年8月，吉瑞製藥與Recordati達成獨家授權合約，在西歐、阿爾及利亞和突尼斯銷售新型非典型抗精神病藥物Cariprazine。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了全球雙相情感障礙治療市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
該報告的目標受群眾外包括行業內的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球雙相情感障礙治療市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

Takeda Pharmaceutical Company Limited
Pfizer, Inc.
Allergan plc.
Otsuka Holdings Co. Ltd.
Johnson & Johnson
Eli Lilly and Company
GlaxoSmithKline plc.
AstraZeneca Plc.
Novartis International AG
AbbVie Inc.
Lundbeck A/S
Minerva Neurosciences
Sumitomo Dainippon Pharma Co., Ltd.
Intra-Cellular Therapies Inc.
Gedeon Richter Plc.
Indivior PLC

第8章

調查方法
關於本公司

簡介目錄

Product Code: CMI2605

Bipolar Disorder treatment Market is estimated to be valued at USD 10,244.9 Mn in 2026 and is expected to reach USD 15,002.2 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 10,244.9 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.60%	2033 Value Projection:	USD 15,002.2 Mn

Bipolar disorder is a lifelong disease, which can be managed with proper medication. The medications used to manage bipolar disorder symptoms include mood stabilizers and atypical antipsychotics. Mood stabilizers such as lithium and other drugs are used for the treatment of bipolar disorders by suppressing mood swings such as mania and depression. Cariprazine is an atypical antipsychotic drug indicated for the treatment of depressive episodes associated with bipolar I disorder in adults. Antidepressant medications are also prescribed to treat depressive episodes in bipolar disorder. Antidepressants combined with mood stabilizers are indicated to prevent the triggering of maniac episodes in patients with bipolar disorder. There is a sudden change in the mood of the patient and his/her ability to carry out daily tasks. There are four types of bipolar disorders: bipolar I, bipolar II, cyclothymic, and other specified and non-specified bipolar and related disorders. People suffering from bipolar disorder experience periods of unusually intense emotion, irregular sleep patterns, and activity levels, and mood episodes. Bipolar disorder is diagnosed based on the patient's symptoms, family history, and life history. The healthcare provider generally conducts a mental health evaluation for the diagnosis of bipolar disorder.

Market Dynamics

The increasing adoption of inorganic growth strategies such as mergers, agreements, and collaborations by key players operating in the market is expected to propel the market growth over the forecast period. For instance, in July 2019, Gedeon Richter plc, entered into an exclusive license agreement with Hikma Pharmaceuticals Plc. to commercialize cariprazine, a novel antipsychotic drug, in certain Middle East and North African or MENA markets. Moreover, earlier in August 2016, Gedeon RichterPlc. and Recordati signed an exclusive license agreement to commercialize cariprazine, a novel atypical antipsychotic drug in Western Europe, Algeria, and Tunisia.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bipolar disorder treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are Takeda Pharmaceutical Company Limited, Pfizer, Inc., Allergan plc, Otsuka Holdings Co. Ltd., Johnson & Johnson, Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca Plc, Novartis International AG, AbbVie Inc., H. Lundbeck A/S, Minerva Neurosciences, Sumitomo Dainippon Pharma Co., Ltd., Intra-Cellular Therapies Inc., Gedeon Richter Plc., and Indivior PLC
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global infection surveillance market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bipolar disorder treatment market

Detailed Segmentation:

Global Bipolar Disorder Treatment Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
Antipsychotics
Antidepressants
Mood Stabilizers
Anti-anxiety Drugs and Others
Global Bipolar Disorder Treatment Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Bipolar Disorder Treatment Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Country:
  - U.S.
  - Canada
Latin America
- By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Country:
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Country:
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
Takeda Pharmaceutical Company Limited*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
Pfizer, Inc.
Allergan plc
Otsuka Holdings Co. Ltd.
Johnson & Johnson
Eli Lilly and Company
GlaxoSmithKline plc
AstraZeneca Plc
Novartis International AG
AbbVie Inc.
Lundbeck A/S
Minerva Neurosciences
Sumitomo Dainippon Pharma Co., Ltd.
Intra-Cellular Therapies Inc.
Gedeon Richter Plc.
Indivior PLC

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Key Highlights
Product Launch
Technological Advancements
PEST Analysis
Regulatory Scenario
Mergers and Acquisitions

4. Global Bipolar Disorder Treatment Market, By Drug Class, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Mood Stabilizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Anti-anxiety Drugs and Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

5. Global Bipolar Disorder Treatment Market, By Distribution Channel, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

6. Global Bipolar Disorder Treatment Market, By Region, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Takeda Pharmaceutical Company Limited *
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Allergan plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Otsuka Holdings Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
GlaxoSmithKline plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AstraZeneca Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Minerva Neurosciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sumitomo Dainippon Pharma Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Intra-Cellular Therapies Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Gedeon Richter Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Indivior PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies